Hypertension, Vol 17, 288-295, Copyright © 1991 by American Heart Association
S Anderson
The intrarenal hemodynamic effects of antihypertensive agents vary
considerably, and these microcirculatory effects may contribute to long-
term structural sequelae in the setting of chronic renal disease. To
investigate the consequences of blood pressure reduction with calcium
antagonists, 5/6 nephrectomized Munich-Wistar rats underwent baseline
determinations of mean arterial pressure, whole kidney function, and single
nephron glomerular filtration rate, after which intravenous infusions of
verapamil or diltiazem were given in doses that acutely normalized blood
pressure; control rats received saline vehicle. During the baseline period,
all rats exhibited comparably elevated values for mean arterial pressure
and single nephron glomerular filtration rate. During the experimental
infusion, control rats exhibited continued single nephron hyperfiltration
(84 +/- 8 nl/min) as a result of elevations in both glomerular capillary
plasma flow rate (330 +/- 36 nl/min) and glomerular capillary hydraulic
pressure (68 +/- 3 mm Hg), whereas the glomerular capillary ultrafiltration
coefficient was low [0.050 +/- 0.009 nl/(sec.mm Hg)]. Both verapamil (148
+/- 6 to 103 +/- 3 mm Hg, p less than 0.05) and diltiazem (154 +/- 6 to 102
+/- 2 mm Hg, p less than 0.05) normalized arterial pressure, which did not
change in control rats (150 +/- 7 to 142 +/- 8 mm Hg). Single nephron
hyperfiltration and hyperperfusion were comparable among groups during the
experimental period; compared with baseline values, diltiazem (97 +/- 8 to
71 +/- 7 nl/min, p less than 0.05) but not verapamil (90 +/- 7 to 83 +/- 6
nl/min, p = NS) modestly lowered the single nephron glomerular filtration
rate.(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass
Renal Division, Brigham and Women's Hospital, Boston, MA 02115.
This article has been cited by other articles:
 |
|
 |
|
  K. Hayashi, S. Wakino, N. Sugano, Y. Ozawa, K. Homma, and T. Saruta Ca2+ Channel Subtypes and Pharmacology in the Kidney Circ. Res., February 16, 2007; 100(3): 342 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Benigni, E. Gagliardini, A. Remuzzi, D. Corna, and G. Remuzzi Angiotensin-Converting Enzyme nhibition Prevents Glomerular-Tubule Disconnection and Atrophy in Passive Heymann Nephritis, an Effect Not Observed with a Calcium Antagonist Am. J. Pathol., November 1, 2001; 159(5): 1743 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. Agodoa, L. Appel, G. L. Bakris, G. Beck, J. Bourgoignie, J. P. Briggs, J. Charleston, D. Cheek, W. Cleveland, J. G. Douglas, et al. Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial JAMA, June 6, 2001; 285(21): 2719 - 2728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. I. Kvam, J. Ofstad, and B. M. Iversen Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR Am J Physiol Renal Physiol, October 1, 1998; 275(4): F576 - F584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Dworkin, E. Tolbert, P. A. Recht, J. C. Hersch, H. Feiner, and R. I. Levin Effects of Amlodipine on Glomerular Filtration, Growth, and Injury in Experimental Hypertension Hypertension, February 1, 1996; 27(2): 245 - 250. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Slataper, N. Vicknair, R. Sadler, and G. L. Bakris Comparative Effects of Different Antihypertensive Treatments on Progression of Diabetic Renal Disease Arch Intern Med, April 26, 1993; 153(8): 973 - 980. [Abstract] [PDF]
|
|
|
|
|
|
M. Epstein Calcium Antagonists and Renal Protection: Current Status and Future Perspectives Arch Intern Med, August 1, 1992; 152(8): 1573 - 1584. [Abstract] [PDF]
|
|
|
|
|
|
V. A. Valentino, M. D. Wilson, W. Weart, and G. L. Bakris A Perspective on Converting Enzyme Inhibitors and Calcium Channel Antagonists in Diabetic Renal Disease Arch Intern Med, December 1, 1991; 151(12): 2367 - 2372. [Abstract] [PDF]
|
|